Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHR NASDAQ:EYPT NYSE:SENS NASDAQ:TXG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHRAehr Test Systems$31.16+0.4%$24.31$6.27▼$34.35$937.67M2.471.26 million shs770,986 shsEYPTEyepoint Pharmaceuticals$13.63-0.7%$12.09$3.91▼$14.91$940.16M1.95825,015 shs132,828 shsSENSSenseonics$0.54+16.4%$0.46$0.25▼$1.40$437.48M0.837.85 million shs9.12 million shsTXG10x Genomics$13.05+2.3%$13.17$6.78▼$20.92$1.63B2.053.26 million shs609,026 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHRAehr Test Systems0.00%+2.75%+21.36%+109.31%+153.02%EYPTEyepoint Pharmaceuticals0.00%-1.22%-2.00%+44.68%+59.10%SENSSenseonics0.00%+0.65%+1.20%-5.38%+34.99%TXG10x Genomics0.00%+8.79%-8.67%+6.96%-36.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHRAehr Test Systems$31.16+0.4%$24.31$6.27▼$34.35$937.67M2.471.26 million shs770,986 shsEYPTEyepoint Pharmaceuticals$13.63-0.7%$12.09$3.91▼$14.91$940.16M1.95825,015 shs132,828 shsSENSSenseonics$0.54+16.4%$0.46$0.25▼$1.40$437.48M0.837.85 million shs9.12 million shsTXG10x Genomics$13.05+2.3%$13.17$6.78▼$20.92$1.63B2.053.26 million shs609,026 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHRAehr Test Systems0.00%+2.75%+21.36%+109.31%+153.02%EYPTEyepoint Pharmaceuticals0.00%-1.22%-2.00%+44.68%+59.10%SENSSenseonics0.00%+0.65%+1.20%-5.38%+34.99%TXG10x Genomics0.00%+8.79%-8.67%+6.96%-36.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHRAehr Test Systems 1.00SellN/AN/AEYPTEyepoint Pharmaceuticals 2.75Moderate Buy$26.8697.04% UpsideSENSSenseonics 3.40Buy$1.54185.25% UpsideTXG10x Genomics 2.25Hold$13.654.65% UpsideCurrent Analyst Ratings BreakdownLatest SENS, TXG, EYPT, and AEHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025AEHRAehr Test SystemsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025EYPTEyepoint PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TXG10x GenomicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/13/2025TXG10x GenomicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/11/2025TXG10x GenomicsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$15.009/5/2025TXG10x GenomicsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/30/2025TXG10x GenomicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/27/2025SENSSenseonicsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$1.508/27/2025SENSSenseonicsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$1.508/14/2025TXG10x GenomicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/12/2025TXG10x GenomicsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$18.00 ➝ $17.00(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHRAehr Test Systems$58.97M15.83$0.11 per share288.51$4.13 per share7.54EYPTEyepoint Pharmaceuticals$51.90M18.10N/AN/A$4.93 per share2.76SENSSenseonics$25.47M17.24N/AN/A$0.07 per share7.70TXG10x Genomics$610.78M2.66N/AN/A$5.81 per share2.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHRAehr Test Systems-$3.91M-$0.13N/A141.61N/A-6.63%-0.15%-0.13%10/6/2025 (Estimated)EYPTEyepoint Pharmaceuticals-$130.87M-$2.68N/AN/AN/A-337.93%-63.80%-50.72%11/6/2025 (Estimated)SENSSenseonics-$60.39M-$0.10N/AN/AN/A-362.30%-842.25%-67.99%N/ATXG10x Genomics-$182.63M-$0.70N/AN/AN/A-13.13%-12.88%-10.03%10/27/2025 (Estimated)Latest SENS, TXG, EYPT, and AEHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/6/2025Q1 2026AEHRAehr Test Systems$0.01N/AN/AN/A$11.47 millionN/A8/7/2025Q2 2025TXG10x Genomics-$0.35$0.28+$0.63$0.28$139.36 million$172.91 million8/6/2025Q2 2025EYPTEyepoint Pharmaceuticals-$0.67-$0.85-$0.18-$0.85$6.82 million$5.33 million7/8/2025Q4 2025AEHRAehr Test Systems-$0.02-$0.01+$0.01-$0.10$14.83 million$14.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHRAehr Test SystemsN/AN/AN/AN/AN/AEYPTEyepoint PharmaceuticalsN/AN/AN/AN/AN/ASENSSenseonicsN/AN/AN/AN/AN/ATXG10x GenomicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEHRAehr Test SystemsN/A5.682.99EYPTEyepoint PharmaceuticalsN/A8.007.91SENSSenseonics59.172.472.38TXG10x GenomicsN/A5.845.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHRAehr Test Systems69.69%EYPTEyepoint Pharmaceuticals99.41%SENSSenseonics12.36%TXG10x Genomics84.68%Insider OwnershipCompanyInsider OwnershipAEHRAehr Test Systems6.80%EYPTEyepoint Pharmaceuticals4.46%SENSSenseonics3.60%TXG10x Genomics10.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHRAehr Test Systems9029.97 million27.93 millionOptionableEYPTEyepoint Pharmaceuticals12068.93 million65.85 millionOptionableSENSSenseonics90814.68 million573.90 millionN/ATXG10x Genomics1,240124.49 million112.00 millionOptionableSENS, TXG, EYPT, and AEHR HeadlinesRecent News About These CompaniesPublic Employees Retirement System of Ohio Raises Position in 10x Genomics $TXGOctober 5 at 3:13 AM | marketbeat.comWall Street Zen Upgrades 10x Genomics (NASDAQ:TXG) to BuyOctober 4 at 3:29 AM | americanbankingnews.com10x Genomics (NASDAQ:TXG) Upgraded to "Buy" at Wall Street ZenOctober 3 at 12:36 AM | marketbeat.com61,470 Shares in 10x Genomics $TXG Purchased by Lecap Asset Management Ltd.October 3 at 5:04 AM | marketbeat.comHead to Head Contrast: Health Catalyst (NASDAQ:HCAT) versus 10x Genomics (NASDAQ:TXG)October 2, 2025 | americanbankingnews.comWealth Enhancement Advisory Services LLC Increases Stock Holdings in 10x Genomics $TXGOctober 2, 2025 | marketbeat.com10x Genomics (NASDAQ:TXG) Receives Average Recommendation of "Hold" from BrokeragesOctober 2, 2025 | americanbankingnews.com10x Genomics (NASDAQ:TXG) Given Average Recommendation of "Hold" by BrokeragesOctober 2, 2025 | marketbeat.com10x Genomics (NASDAQ:TXG) Trading Up 7.1% - Still a Buy?October 1, 2025 | marketbeat.com78,249 Shares in 10x Genomics $TXG Purchased by Counterpoint Mutual Funds LLCSeptember 23, 2025 | marketbeat.com10x Genomics $TXG Shares Sold by Assenagon Asset Management S.A.September 23, 2025 | marketbeat.comPallas Capital Advisors LLC Acquires 32,996 Shares of 10x Genomics $TXGSeptember 20, 2025 | marketbeat.com10x Genomics $TXG Stake Raised by Goldman Sachs Group Inc.September 17, 2025 | marketbeat.comWeiss Ratings Reaffirms "Sell (E+)" Rating for 10x Genomics (NASDAQ:TXG)September 17, 2025 | marketbeat.com10x Genomics: Surprise Profitability May Be Temporary, But It's Still A Welcome SignSeptember 16, 2025 | seekingalpha.comKera Capital Partners Inc. Makes New Investment in 10x Genomics $TXGSeptember 16, 2025 | marketbeat.comAcadian Asset Management LLC Boosts Stake in 10x Genomics $TXGSeptember 16, 2025 | marketbeat.com10x Genomics $TXG Stock Position Raised by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLCSeptember 16, 2025 | marketbeat.com10x Genomics (NASDAQ:TXG) Cut to "Hold" at Wall Street ZenSeptember 15, 2025 | marketbeat.com10x Genomics $TXG Shares Purchased by AmundiSeptember 14, 2025 | marketbeat.com10x Genomics (NASDAQ:TXG) Now Covered by Analysts at Piper SandlerSeptember 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Cybersecurity Market Set to Double: This ETF Offers ExposureBy Jordan Chussler | September 24, 2025Lululemon’s Sell-Off Looks Overdone: A Contrarian CaseBy Sam Quirke | September 16, 2025SENS, TXG, EYPT, and AEHR Company DescriptionsAehr Test Systems NASDAQ:AEHR$31.16 +0.14 (+0.44%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aehr Test Systems provides test solutions for testing, burning-in, and semiconductor devices in wafer level, singulated die, and package part form, and installed systems worldwide. Its product portfolio includes FOX-XP and FOX-NP systems that are full wafer contact and singulated die/module test and burn-in systems that can test, burn-in, and stabilize range of devices, including silicon carbide-based and other power semiconductors, 2D and 3D sensors used in mobile phones, tablets and other computing devices, memory semiconductors, processors, microcontrollers, systems-on-a-chip, and photonics and integrated optical devices. The company also offers FOX-CP system, a low-cost single-wafer compact test solution for logic, memory, and photonic devices; FOX WaferPak Contactor, a full wafer contactor capable of testing wafers up to 300mm that enables integrated circuit manufacturers to perform test, burn-in, and stabilization of full wafers on the FOX-P systems. In addition, it provides FOX DiePak Carrier, a reusable temporary package that enables IC manufacturers to perform final test and burn-in of bare die and modules; and FOX DiePak Loader. The company was incorporated in 1977 and is headquartered in Fremont, California.Eyepoint Pharmaceuticals NASDAQ:EYPT$13.63 -0.10 (-0.73%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Senseonics NYSE:SENS$0.54 +0.08 (+16.41%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.10x Genomics NASDAQ:TXG$13.05 +0.30 (+2.33%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Behind D-Wave's Massive Week (And Why Rivals Also Popped) Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength Broadcom’s VMware Push Takes Aim at Microsoft, Google, & Amazon How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
